Precision Therapeutics for Endometriosis
Reimagining endometriosis treatment at the source.
Esma Bio is developing a novel targeted therapeutic platform designed to silence the molecular drivers of endometriosis — without the hormonal suppression, bone loss, or duration limits of current care.
190M
women affected globally
7–10 yrs
average diagnostic delay
~50%
post-treatment recurrence
The Unmet Need
Endometriosis has been stuck in a hormonal paradigm for decades.
Affecting nearly 190 million women globally, endometriosis remains one of the most underserved diseases in modern medicine. The standard of care has not meaningfully evolved in a generation.
190M
women affected globally
7–10 yrs
average diagnostic delay
~50%
post-treatment recurrence
Disease Burden
A debilitating disease, often invisible
Endometriosis causes chronic pelvic pain, infertility, and systemic inflammation. Patients endure years of misdiagnosis before reaching a specialist, and many lose career years and quality of life to a disease that is still poorly understood and undertreated.
Treatment Limitations
Hormones and surgery — neither is a cure
Existing therapies suppress estrogen system-wide, carrying bone-density and tolerability penalties that limit their duration of use. Surgery is invasive and the disease frequently recurs. No therapy on the market addresses the underlying biology of the lesion itself.
The Esma Bio Approach
Beyond hormones and surgery.
Esma Bio is building a precision approach to the molecular drivers of endometriosis — designed to suppress local estrogen biosynthesis within endometriotic lesions while sparing ovarian and systemic estrogen production.
Novel
A new mechanistic class for a disease where the standard of care has barely changed in decades.
Targeted
Lesion-selective targeting designed to act where the disease lives — not across the whole endocrine system.
Non-Hormonal
Does not suppress the hypothalamic–pituitary–gonadal axis. No induced menopause, no bone-density penalty.
Differentiated
Disease-modifying rather than symptom-managing — with the potential for durable effect and infrequent dosing.
Development Roadmap
From candidate to clinic.
Candidate Selection
Complete
In Vitro Validation
In Progress
In Vivo Proof of Concept
Planned
IND-Enabling Studies
Planned
First-in-Human
Planned
Candidate Selection
Complete
In Vitro Validation
In Progress
In Vivo Proof of Concept
Planned
IND-Enabling Studies
Planned
First-in-Human
Planned
Detailed timelines and regulatory strategy are shared with qualified partners under CDA.
Why Now
A category-defining opportunity, finally.
Several long-running trends in biology, medicine, and capital markets are converging to make endometriosis newly tractable.
Women's Health Momentum
Capital, regulatory attention, and clinical infrastructure for women's health are finally catching up to the disease burden.
Precision Medicine Gap
Endometriosis has been bypassed by the precision therapeutics revolution that reshaped oncology and rare disease.
Therapeutic White Space
No new mechanistic class has been approved for endometriosis in a generation, leaving a wide-open differentiation lane.
Market Validation
Recent women's health programs and acquisitions have re-rated the space — establishing endometriosis as a fundable category.